Literature DB >> 17028890

Clinical validity of the Japanese version of the Functional Assessment of Cancer Therapy-Anemia Scale.

Maya Kurita1, Kojiro Shimozuma, Satoshi Morita, Yuki Fujiki, Kenichi Ishizawa, Hisae Eguchi, Yuko Saito, Nobuko Ushirozawa, Izumi Wasada, Yasuo Ohashi, Kenji Eguchi.   

Abstract

GOALS OF WORK: The purpose of this study was to reveal the clinical validity of the Japanese version of the Functional Assessment of Cancer Therapy-Anemia scale (FACT-An) in relation to hemoglobin level. We also analyzed patients' scores for the related FACT-General scale (FACT-G), the FACT Anemia subscale, and the FACT Trial Outcome Index-Anemia scale (FACT TOI-An) to determine which was the most sensitive to anemia measurements.
MATERIALS AND METHODS: Throughout Japan, we recruited 227 patients (mean+/-SD, 59+/-12.1 years old) diagnosed with a variety of cancers. We correlated the severity of anemia, as measured by hemoglobin levels, to scores on the FACT-An and on the other scales at baseline and at 3 months. MAIN
RESULTS: The questionnaire completion rate was more than 98% at both time points. The FACT-An had high internal consistency (Cronbach's alpha coefficient >0.8). FACT-An scores were significantly and positively correlated with hemoglobin levels both at baseline (r=0.24; 95% CI=0.12 to 0.36; n=225) and at 3 months (r=0.24; 95% CI=0.10 to 0.36; n=204). FACT-G, FACT Anemia subscale, and FACT TOI-An scores also successfully discriminated between patients with lower (Hb <11.0 g/dl) and higher (Hb > or =11.0 g/dl) hemoglobin levels. Moreover, the changes of these FACT scores over 3-months could discriminate changes in hemoglobin level.
CONCLUSION: The Japanese version of the FACT-An has higher clinical validity and can be used to appropriately assess health-related quality of life among Japanese cancer patients with anemia.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17028890     DOI: 10.1007/s00520-006-0138-2

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  10 in total

1.  The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue.

Authors:  D Cella
Journal:  Semin Hematol       Date:  1997-07       Impact factor: 3.851

2.  Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial.

Authors:  T J Littlewood; E Bajetta; J W Nortier; E Vercammen; B Rapoport
Journal:  J Clin Oncol       Date:  2001-06-01       Impact factor: 44.544

3.  Cross-cultural validation of an international questionnaire, the General Measure of the Functional Assessment of Cancer Therapy scale (FACT-G), for Japanese.

Authors:  H Fumimoto; K Kobayashi; C H Chang; S Eremenco; Y Fujiki; S Uemura; Y Ohashi; S Kudoh
Journal:  Qual Life Res       Date:  2001       Impact factor: 4.147

4.  Cross-cultural validation of the Japanese Functional Assessment of Cancer Therapy-Anemia (FACT-An).

Authors:  Akinobu Yoshimura; Kunihiko Kobayashi; Hiyori Fumimoto; Yuki Fujiki; Sonya Eremenco; Shoji Kudoh
Journal:  J Nippon Med Sch       Date:  2004-10       Impact factor: 0.920

5.  Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy.

Authors:  Jeffrey Crawford; David Cella; Charles S Cleeland; Pierre-Yves Cremieux; George D Demetri; Brenda J Sarokhan; Mitchell B Slavin; John A Glaspy
Journal:  Cancer       Date:  2002-08-15       Impact factor: 6.860

6.  The Functional Assessment of Cancer Therapy scale: development and validation of the general measure.

Authors:  D F Cella; D S Tulsky; G Gray; B Sarafian; E Linn; A Bonomi; M Silberman; S B Yellen; P Winicour; J Brannon
Journal:  J Clin Oncol       Date:  1993-03       Impact factor: 44.544

7.  Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy.

Authors:  Thomas E Witzig; Peter T Silberstein; Charles L Loprinzi; Jeff A Sloan; Paul J Novotny; James A Mailliard; Kendrith M Rowland; Steven R Alberts; James E Krook; Ralph Levitt; Roscoe F Morton
Journal:  J Clin Oncol       Date:  2004-09-27       Impact factor: 44.544

8.  Reliability and validity of the Functional Assessment of Chronic Illness Therapy-Spiritual (FACIT-Sp) for Japanese patients with cancer.

Authors:  Wataru Noguchi; Tatsuya Ohno; Satoshi Morita; Okihiko Aihara; Hirohiko Tsujii; Kojiro Shimozuma; Eisuke Matsushima
Journal:  Support Care Cancer       Date:  2004-01-23       Impact factor: 3.603

9.  Reliability and validity of the Functional Assessment of Cancer Therapy-Lung (FACT-L) quality of life instrument.

Authors:  D F Cella; A E Bonomi; S R Lloyd; D S Tulsky; E Kaplan; P Bonomi
Journal:  Lung Cancer       Date:  1995-06       Impact factor: 5.705

10.  Epoetin alfa treatment results in clinically significant improvements in quality of life in anemic cancer patients when referenced to the general population.

Authors:  David Cella; Martin J Zagari; Christina Vandoros; Dennis D Gagnon; Hans-Jürgen Hurtz; Johan W R Nortier
Journal:  J Clin Oncol       Date:  2003-01-15       Impact factor: 44.544

  10 in total
  1 in total

1.  Prevalence and incidence of anemia in Japanese cancer patients receiving outpatient chemotherapy.

Authors:  Toshiyuki Kitano; Harue Tada; Tsutomu Nishimura; Satoshi Teramukai; Masashi Kanai; Takafumi Nishimura; Akiko Misawa; Kiyotsugu Yoshikawa; Hiroyasu Yasuda; Hiroshi Ishiguro; Shigemi Matsumoto; Kazuhiro Yanagihara; Masanori Fukushima
Journal:  Int J Hematol       Date:  2007-07       Impact factor: 2.490

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.